For example, in a recent retrospective analysis, including 302 stage III/IV NSCLC-affected patients, 25 of which were STK11-mutated, 13 out of the 25 presented a KRAS co-mutation (52%, p = 0.0008). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.